November 23, 2020
Tony Hagen
Pfizer aims to begin marketing Nyvepria in the European Union in the first quarter of 2021.
November 21, 2020
Bincy P. Abraham, MD
Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.
November 15, 2020
Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars.
October 29, 2020
The American College of Rheumatology (ACR) has joined with other provider groups in opposing a UnitedHealthcare (UHC) plan that could increase patient out-of-pocket costs.
October 26, 2020
A study of mandatory switching for patients with rheumatologic conditions led to savings without effect on safety or efficacy.
October 24, 2020
Deana Ferreri, PhD
European investigators have derived a set of core principals for developing higher utilization of biosimilars.
October 22, 2020
Skylar Jeremias
Overcoming biosimilar uptake barriers will take collaboration and policy change by hospitals, infusion clinics, and health plans, presenters said at the Academy of Managed Care Pharmacy Nexus 2020 Virtual conference.
October 12, 2020
Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.
October 5, 2020
During the coronavirus disease 2019 (COVID-19) pandemic, patients are more likely to have delayed cancer screenings rather than their doctors and clinics.
September 25, 2020
Debra Patt, MD, PhD, MBA, discusses issues affecting biosimilar uptake at the Patient-Centered Oncology Care® 2020 virtual conference.
